Anaphylaxis Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Nasus Pharma, Amphastar Pharmaceuticals Inc., Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics

DelveInsight's "Anaphylaxis Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock key insights into the Anaphylaxis Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Anaphylaxis Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Anaphylaxis Market Report
• In March 2025, the FDA approved the expanded use of ARS Pharmaceuticals' Neffy nasal spray for severe allergic reactions in patients weighing between 15 and 30 kg. First approved in August, Neffy offers an alternative to EpiPen and other epinephrine autoinjectors, designed for use at the first sign of a severe allergic reaction to prevent life-threatening conditions like anaphylaxis.
• According to available literature, Anaphylaxis affects equally both females and males.
• Yu et al. (2018) conducted a study titled "The Epidemiology of Anaphylaxis", wherein the lifetime prevalence of anaphylaxis was estimated at 0.05-2% in the USA and approximately 3% in Europe.
• National Institute For Health And Care Excellence (NICE) (2015), stated that between March 2013 and February 2014 approximately 1 in 5 admissions to hospitals in England due to allergies were for an anaphylactic reaction (4070 out of 20,318). This was an increase of 9.9% compared to the previous year. The NICE CG134 guideline reported an available UK estimate that about 1 in 1,333 of the population of England had experienced anaphylaxis at some point in their lives. However, a systematic review published in 2013 estimated that 1 in 300 people in Europe were affected by anaphylaxis at some point in their lives.
• The increase in Anaphylaxis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Anaphylaxis Market is anticipated to witness growth at a considerable CAGR.
• The leading Anaphylaxis Companies such as Nasus Pharma, Amphastar Pharmaceuticals Inc., Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics and others.
• Promising Anaphylaxis Pipeline Therapies such as Acalabrutinib, AQST-109, AQST-108, and others

Stay ahead in the competitive landscape of the Anaphylaxis Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Anaphylaxis Treatment Market Size- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anaphylaxis Epidemiology Segmentation in the 7MM
The epidemiology section of Anaphylaxis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Anaphylaxis epidemiology trends @ Anaphylaxis Prevalence- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Emerging Anaphylaxis Drugs
• Acalabrutinib: AstraZeneca
Acalabrutinib is being investigated by AstraZeneca, Calquence (acalabrutinib; previously known as ACP-196) is a selective inhibitor of BTK. Calquence binds covalently to BTK, thereby inhibits its activity. The trial is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adult. Currently the trial is in Phase II and the primary outcome will measure change in the highest dose of peanut or tree nut that is tolerated during oral food challenge before and after taking acalabrutinib.

• AQST-108: Aquestive Therapeutics
AQST-108, is being investigated by Aquestive Therapeutics. It is a "first of its kind" oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis. AQST-108-SF is composed of the prodrug dipivefrin, which is contained within a unique polymeric matrix of Aquestive's Pharmfilm technology. The company submitted an IND for AQST-108-SF to the FDA in June 2020.

• AQST-109: Aquestive Therapeutics
AQST-109 is a next generation prodrug sublingual film formulation of epinephrine that Aquestive intends to develop for treatment of allergic reactions including anaphylaxis. In vitro tests and preclinical studies indicate that AQST-109-SF has the potential to absorb more extensively, convert more rapidly to systemic epinephrine, utilize less drug and provide a unique profile when compared to AQST-108-SF. In March 2022, the company reported a continued rapid absorption of AQST-109 as exemplified by the data from Parts 1 and 2 of the EPIPHAST study.

Anaphylaxis Drugs Market
The Anaphylaxis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Anaphylaxis signaling in Anaphylaxis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Anaphylaxis Treatment Market Landscape
The Anaphylaxis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Anaphylaxis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Anaphylaxis treatment guidelines, visit @ Anaphylaxis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Anaphylaxis Companies
Nasus Pharma, Amphastar Pharmaceuticals Inc., Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics and others

Anaphylaxis Market Outlook
The report's outlook on the Anaphylaxis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Anaphylaxis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Anaphylaxis drug and late-stage pipeline therapy.

Anaphylaxis Drugs Uptake
The drug chapter of the Anaphylaxis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Anaphylaxis.

Explore the dynamics of the Anaphylaxis Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Anaphylaxis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Anaphylaxis Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Anaphylaxis Companies- Nasus Pharma, Amphastar Pharmaceuticals Inc., Aravax Pty Ltd, AstraZeneca, Aquestive Therapeutics and others
• Anaphylaxis Pipeline Therapies- Acalabrutinib, AQST-109, AQST-108, and others
• Anaphylaxis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Anaphylaxis Unmet Needs, KOL's views, Analyst's views, Anaphylaxis Market Access and Reimbursement

To know more about Anaphylaxis Companies working in the treatment market, visit @ Anaphylaxis Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/anaphylaxis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Executive Summary of Anaphylaxis
3. Competitive Intelligence Analysis for Anaphylaxis
4. Anaphylaxis: Market Overview at a Glance
5. Anaphylaxis: Disease Background and Overview
6. Anaphylaxis Patient Journey
7. Anaphylaxis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Anaphylaxis Unmet Needs
10. Key Endpoints of Anaphylaxis Treatment
11. Anaphylaxis Marketed Products
12. Anaphylaxis Emerging Therapies
13. Anaphylaxis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Anaphylaxis Market Outlook
16. Access and Reimbursement Overview of Anaphylaxis
17. Anaphylaxis KOL Views
18. Anaphylaxis Market Drivers
19. Anaphylaxis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Periodontal disease market- https://www.delveinsight.com/report-store/periodontal-disease-market
Surgical energy instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
NK Cell Therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.